Cancer Research Institute
Clinical Trials
A Randomized Phase II Study of Nivolumab after Combined Modality Therapy (CMT) in High Risk Anal Cancer
The purpose of this study is to find if adding the study drug, nivolumab (also known as OPDIVO), after standard chemotherapy {(mitomycin-C and 5-fluorouracil 5(-RU) or capecitabine) or 5-FU and cisplatin} and radition will prev ...
A randomized, three-arm, double-blind, placebo-controlled, phase III study, comparing NIS793 with or without spartalizumab in combination with gemcitabine and nab-paclitaxel versus matching placebos combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC)
The purpose of this study is to evaluate the efficacy and safety of NIS793 in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel and placebo in first-line mPDAC. This study aims to explore whether blo ...
A021502 Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
The purpose of this study is to compare any good and bad effects of using the drug atezolizumab along with the usual chemotherapy compared to the usual chemotherapy alone. The addition of atezolizumab to the usual chemotherapy ...
An open-label, multi-center, phase II platform study evaluating the efficacy and safety of NIS793 and other new investigational drug combinations with standard of care (SOC) anti-cancer therapy for the second line treatment of metastatic colorectal cancer
We are inviting you to be in a research study to find out if adding an investigational compound NIS793 by itself or in combination with a compound tislelizumab to standard anti-cancer therapy can potentially improve treatment o ...
APEC1621K NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients with Tumors Harboring IDH1 Mutations.
The main goal is to find out what effect, good and/or bad effects AG-120 (ivosidenib) on your tumor. A second goal of the study is to evaluate side effects that might be caused by AG-120 (ivosidenib), which could shrink your ca ...
Association of ctDNA and circulating tumor cells after neoadjuvant chemotherapy with disease recurrence in patients with advanced stage epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
To compare the levels of ctDNA and CTCs using the SIGNATERA™ test in the peripheral blood of patients during neoadjuvant chemotherapy and after IDS for advanced stage epithelial ovarian carcinoma. Blood samples will be collecte ...
BO40729: An Open Label, Multicenter Extension Study In Patients Previously Enrolled In A Genentech And/Or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study(IMBRELLA B) (roll-over to YO40482)
You are being asked to take part in this research study (also known as a clinical trial) because you have cancer and you have been in an atezolizumab study (hereafter referred to as the parent study) sponsored by Genentech Inc. ...
Caris Molecular Intelligence and Caris Centers of Excellence for Precision Medicine Network Outcomes Associated Repository
The purpose of the research repository is to collect information, which will be used for research studies to evaluate how clinical outcomes relate to Caris Molecular INtelligence Services.
EA1181 (CompassHER2-pCR): Preoperative THP and postoperative HP in Patients who Achieve a Pathologic Complete Response, Part 1 Component of: The CompassHER2 Trials (COMprehensive use of Pathologic Response ASSessment to Optimize Therapy in HER2-positive Breast Cancer)
This study is being done to answer the following question. Can participants with HER2-positive breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after 12 weeks of chemotherapy ...